Unknown

Dataset Information

0

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study.

ABSTRACT:

SUBMITTER: Wurm S 

PROVIDER: S-EPMC12546751 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.
| S-EPMC10523977 | biostudies-literature
Unknown Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
| S-EPMC11815990 | biostudies-literature
Unknown Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
| S-EPMC10514257 | biostudies-literature
Unknown AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax.
| S-EPMC9240361 | biostudies-literature
Unknown Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
| S-EPMC11416634 | biostudies-literature
Unknown Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
| S-EPMC11045980 | biostudies-literature
Unknown Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
| S-EPMC11216982 | biostudies-literature
Unknown Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
| S-EPMC9481998 | biostudies-literature
Unknown Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.
| S-EPMC11886493 | biostudies-literature
Unknown Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.
| S-EPMC12006504 | biostudies-literature